Fulgent Reports Second Quarter 2024 Financial Results
Fulgent Genetics (NASDAQ: FLGT) reported Q2 2024 financial results with total revenue of $71.0 million. Core Revenue grew 5% year-over-year to $70.2 million. The company reported a GAAP loss of $8.7 million, or ($0.29) per share, and Non-GAAP income of $4.7 million, or $0.15 per share. Fulgent reiterated its Full Year 2024 Core Revenue Guidance of $280 million and improved its Earnings Per Share Guidance. The company maintains a strong cash position with $837.9 million in cash, cash equivalents, and investments as of June 30, 2024. Fulgent's Laboratory Services continue to show strength, particularly in Precision Diagnostics, while its Therapeutics Development segment progresses with clinical trials.
Fulgent Genetics (NASDAQ: FLGT) ha comunicato i risultati finanziari del secondo trimestre del 2024 con un fatturato totale di 71,0 milioni di dollari. Il fatturato principale è cresciuto del 5% rispetto all'anno precedente, raggiungendo 70,2 milioni di dollari. L'azienda ha riportato una perdita GAAP di 8,7 milioni di dollari, corrispondente a ($0,29) per azione, e un reddito Non-GAAP di 4,7 milioni di dollari, ovvero $0,15 per azione. Fulgent ha ribadito la sua guida per il fatturato principale per l'intero anno 2024 di 280 milioni di dollari e ha migliorato le sue previsioni sugli utili per azione. L'azienda mantiene una solida posizione di liquidità con 837,9 milioni di dollari in contante, equivalenti in contante e investimenti al 30 giugno 2024. I servizi di laboratorio di Fulgent continuano a mostrare risultati positivi, in particolare nella diagnostica di precisione, mentre il segmento dello sviluppo terapeutico avanza con studi clinici.
Fulgent Genetics (NASDAQ: FLGT) informó los resultados financieros del segundo trimestre de 2024 con un ingreso total de 71,0 millones de dólares. Los ingresos centrales crecieron un 5% interanual, alcanzando 70,2 millones de dólares. La compañía reportó una pérdida GAAP de 8,7 millones de dólares, o ($0,29) por acción, y un ingreso No-GAAP de 4,7 millones de dólares, o $0,15 por acción. Fulgent reafirmó su guía de ingresos centrales para el año completo 2024 de 280 millones de dólares y mejoró su guía de ganancias por acción. La empresa mantiene una sólida posición de liquidez con 837,9 millones de dólares en efectivo, equivalentes de efectivo e inversiones a 30 de junio de 2024. Los servicios de laboratorio de Fulgent continúan mostrando fortaleza, particularmente en Diagnósticos de Precisión, mientras que su segmento de Desarrollo Terapéutico avanza con ensayos clínicos.
풀젠트 유전자(Fulgent Genetics, NASDAQ: FLGT)는 2024년 2분기 재무 결과로 총 매출이 7,100만 달러에 달한다고 발표했습니다. 핵심 매출은 전년 대비 5% 증가하여 7,020만 달러에 이르렀습니다. 회사는 GAAP 기준으로 870만 달러의 손실, 즉 주당 ($0.29)로 보고했으며, 비GAAP 기준으로는 470만 달러의 수익, 즉 주당 $0.15를 기록했습니다. 풀젠트는 2024년 전체 연도에 대한 핵심 매출 안내를 2억 8,000만 달러로 재확인하고, 주당 수익 안내를 개선했습니다. 2024년 6월 30일 기준으로 8억 3,790만 달러의 현금, 현금성 자산 및 투자를 보유하여 강력한 현금 위치를 유지하고 있습니다. 풀젠트의 실험실 서비스는 정밀 진단 분야에서 특히 강세를 보이며, 치료 개발 부문은 임상 시험을 진행하고 있습니다.
Fulgent Genetics (NASDAQ: FLGT) a rapporté les résultats financiers du deuxième trimestre 2024 avec un chiffre d'affaires total de 71,0 millions de dollars. Le chiffre d'affaires principal a augmenté de 5 % d'une année sur l'autre, atteignant 70,2 millions de dollars. L'entreprise a enregistré une perte GAAP de 8,7 millions de dollars, soit ($0,29) par action, et un revenu Non-GAAP de 4,7 millions de dollars, soit $0,15 par action. Fulgent a réitéré ses prévisions de chiffre d'affaires principal pour l'année complète 2024 de 280 millions de dollars et a amélioré ses prévisions de bénéfice par action. L'entreprise maintient une solide position de trésorerie avec 837,9 millions de dollars en liquidités, équivalents de liquidités et investissements au 30 juin 2024. Les services de laboratoire de Fulgent continuent de montrer des forces, notamment dans le domaine du diagnostic de précision, tandis que son segment de développement thérapeutique progresse avec des essais cliniques.
Fulgent Genetics (NASDAQ: FLGT) berichtete über die finanziellen Ergebnisse des 2. Quartals 2024 mit einem Gesamterlös von 71,0 Millionen US-Dollar. Der Kernerlös wuchs im Jahresvergleich um 5 % auf 70,2 Millionen US-Dollar. Das Unternehmen wies einen GAAP-Verlust von 8,7 Millionen US-Dollar, oder ($0,29) pro Aktie, und ein Non-GAAP-Einkommen von 4,7 Millionen US-Dollar, also $0,15 pro Aktie aus. Fulgent bekräftigte seine Prognose für den Kernerlös für das Gesamtjahr 2024 von 280 Millionen US-Dollar und verbesserte die Prognose für das Ergebnis pro Aktie. Das Unternehmen weist eine starke Liquiditätsposition mit 837,9 Millionen US-Dollar an liquiden Mitteln, liquiden Mittelnäquivalenten und Investitionen zum 30. Juni 2024 auf. Die Labordienstleistungen von Fulgent zeigen weiterhin Stärke, insbesondere im Bereich der Präzisionsdiagnostik, während der Therapeutik-Entwicklungsbereich mit klinischen Studien vorankommt.
- Core Revenue grew 5% year-over-year to $70.2 million
- Non-GAAP income of $4.7 million, or $0.15 per share
- Strong cash position with $837.9 million in cash, cash equivalents, and investments
- Reiterated Full Year 2024 Core Revenue Guidance of $280 million
- Improved Earnings Per Share Guidance for 2024
- Positive momentum in Precision Diagnostics segment
- Initial enrollment in Phase 2 trial of FID-007 for Head and Neck Cancer
- GAAP loss of $8.7 million, or ($0.29) per share
- Adjusted EBITDA loss of $727,000
Insights
Fulgent Genetics' Q2 2024 results present a mixed picture. The company's core revenue grew by
The company's cash position remains strong, with
Fulgent has reiterated its full-year 2024 core revenue guidance of
The transition from COVID-19 testing to core business operations appears to be progressing, but investors should monitor how quickly Fulgent can achieve profitability in its core operations. The company's investment in therapeutics development, particularly the Phase 2 trial of FID-007 in Head and Neck Cancer, represents a potential growth avenue but also carries inherent risks and costs associated with drug development.
Fulgent's Q2 2024 results highlight the company's strategic shift towards precision diagnostics and therapeutics development. The momentum in Precision Diagnostics is particularly noteworthy, as it represents a high-growth area in personalized medicine.
The initial enrollment in the Phase 2 trial of FID-007 for Head and Neck Cancer is a significant milestone. Head and neck cancers are notoriously difficult to treat and new therapeutic options are sorely needed. If successful, this could position Fulgent as a player in the oncology therapeutics market.
The company's progress with FID-022, moving towards an Investigational New Drug (IND) application by the end of 2024, demonstrates a growing pipeline. This diversification into therapeutics development could provide long-term value, but it also increases the company's risk profile and cash burn rate.
Investors should closely monitor the progress of these clinical trials and the associated costs. While the potential rewards in therapeutics are high, the path to market is long and uncertain. Fulgent's strong cash position provides a buffer, but the company will need to balance its investments in therapeutics with maintaining profitability in its core diagnostics business.
-
Total Revenue of
$71.0 million -
Core Revenue grows
5% year-over-year to$70.2 million -
Reiterates Full Year 2024 Core Revenue Guidance of
, Improves Earnings Per Share Guidance for 2024$280 million
Second Quarter 2024 Results:
-
Total Revenue of
$71.0 million -
Core Revenue1 grew
5% year-over-year to$70.2 million -
GAAP loss of
, or ($8.7 million ) per share$0.29 -
Non-GAAP income of
, or$4.7 million per share$0.15 -
Adjusted EBITDA loss of
$727,000 -
Cash from operations of
$4.3 million -
Cash, cash equivalents, and investments in marketable securities of
as of June 30, 2024$837.9 million
Note:
1) Core Revenue is revenue calculated in accordance with GAAP minus revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue, each as calculated in accordance with GAAP.
Non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), GAAP gross profit and margin, and GAAP operating income (loss) and margin, in the accompanying tables.
Ming Hsieh, Chairperson of the Board of Directors and Chief Executive Officer, said, “Laboratory Services continue to be a source of strength for Fulgent, fueling our initiatives and business model, with momentum in Precision Diagnostics. In Therapeutics Development, we are off to a good start with initial enrollment of our Phase 2 trial of FID-007 in Head and Neck Cancer, and we continue to move our next candidate, FID-022, through preclinical studies toward an Investigational New Drug (IND) application by the end of 2024. In the meantime, with our projected revenue from Laboratory Services, we believe we are well-positioned to execute our strategy.”
Paul Kim, Chief Financial Officer, said, “We continue to be on track with the operational objectives we set at the beginning of 2024, remaining in an enviable cash position with flexibility to execute.”
Outlook:
For the full year 2024, Fulgent expects:
-
Core Revenue of approximately
$280 million -
GAAP loss improvement from approximately (
) per share to approximately ($2.25 ) per share$1.95 -
Non-GAAP loss improvement from approximately (
) per share to approximately ($1.05 ) per share$0.30 -
Cash, cash equivalents, and investments in marketable securities of approximately
as of December 31, 2024*$800 million
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program or other expenditures outside the ordinary course of business.
Conference Call Information
Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its second quarter 2024 results. The call may be accessed through a live audio webcast in the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
Note Regarding Non-GAAP Financial Measures
Certain information set forth in this press release and/or to be discussed on the Company’s earnings call, including non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin are non-GAAP financial measures. Fulgent believes this information is useful to investors because it provides a basis for measuring the performance of the Company’s business, excluding certain income or expense items that management believes are not directly attributable to the Company’s operating results. Fulgent defines non-GAAP income (loss) as net income (loss) calculated in accordance with accounting principles generally accepted in
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; guidance regarding expected quarterly and annual financial results, core revenues, GAAP loss, non-GAAP loss, and cash, cash equivalents and investments in marketable securities; evaluations and judgments regarding the stability of certain revenue sources, the Company’s cash position and sufficiency of its resources, momentum, trajectory, vision, future opportunities and future growth of the Company’s testing and laboratory services, technologies and expansion; the Company’s research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials, including any implication that interim or preliminary data will be representative of final data; the Company’s identification and evaluation of opportunities and its ability to capitalize on opportunities, capture market share, or expand its presence in certain markets; and the Company’s ability to continue to grow its business.
Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the Company’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on the Company’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the market potential for, and the rate and degree of market adoption of, the Company’s tests; its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the Company’s ability to maintain the low internal costs of its business model; the Company’s ability to maintain an acceptable margin; risks related to volatility in the Company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the Company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the Company’s revenue; the Company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests and testing services; the Company’s level of success in establishing and obtaining the intended benefits from partnerships, strategic investments, joint ventures, acquisitions, or other relationships; the success of the Company’s development efforts, including the Company’s ability to progress its candidates through clinical trials on the timelines expected; the Company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and the Company’s ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.
The forward-looking statements made in this press release speak only as of the date of this press release, and the Company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.
The Company’s reports filed with the
FULGENT GENETICS, INC. |
|
|
|
|
||||
Condensed Consolidated Balance Sheet Data |
|
|
|
|
||||
June 30, 2024 and December 31, 2023 |
|
|
|
|
||||
(in thousands) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
June 30, 2024 |
|
December 31, 2023 |
||||
ASSETS: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
65,111 |
|
|
$ |
97,473 |
|
Investments in marketable securities |
|
|
772,758 |
|
|
750,252 |
||
Accounts receivable, net |
|
|
56,573 |
|
|
|
51,132 |
|
Property, plant, and equipment, net |
|
|
93,368 |
|
|
|
83,464 |
|
Other assets |
|
|
244,429 |
|
|
|
253,007 |
|
Total assets |
|
$ |
1,232,239 |
|
|
$ |
1,235,328 |
|
LIABILITIES & EQUITY: |
|
|
|
|
||||
Accounts payable, accrued liabilities and other liabilities |
|
$ |
103,391 |
|
|
$ |
102,042 |
|
Total stockholders’ equity |
|
|
1,128,848 |
|
|
|
1,133,286 |
|
Total liabilities & equity |
|
$ |
1,232,239 |
|
|
$ |
1,235,328 |
|
FULGENT GENETICS, INC. |
||||||||||||||||
Condensed Consolidated Statement of Operations Data |
||||||||||||||||
Three and Six Months Ended June 30, 2024 and 2023 |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
(unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Revenue |
|
$ |
71,028 |
|
|
$ |
67,853 |
|
|
$ |
135,513 |
|
|
$ |
134,021 |
|
Cost of revenue (1) |
|
|
44,537 |
|
|
|
47,281 |
|
|
|
86,918 |
|
|
|
94,638 |
|
Gross profit |
|
|
26,491 |
|
|
|
20,572 |
|
|
|
48,595 |
|
|
|
39,383 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Research and development (1) |
|
|
13,486 |
|
|
|
9,692 |
|
|
|
24,920 |
|
|
|
19,474 |
|
Selling and marketing (1) |
|
|
8,595 |
|
|
|
10,723 |
|
|
|
17,584 |
|
|
|
20,806 |
|
General and administrative (1) |
|
|
21,326 |
|
|
|
17,993 |
|
|
|
42,815 |
|
|
|
39,795 |
|
Amortization of intangible assets |
|
|
1,990 |
|
|
|
1,962 |
|
|
|
3,980 |
|
|
|
3,930 |
|
Total operating expenses |
|
|
45,397 |
|
|
|
40,370 |
|
|
|
89,299 |
|
|
|
84,005 |
|
Operating loss |
|
|
(18,906 |
) |
|
|
(19,798 |
) |
|
|
(40,704 |
) |
|
|
(44,622 |
) |
Interest and other income, net |
|
|
7,692 |
|
|
|
5,098 |
|
|
|
15,317 |
|
|
|
8,873 |
|
Loss before income taxes |
|
|
(11,214 |
) |
|
|
(14,700 |
) |
|
|
(25,387 |
) |
|
|
(35,749 |
) |
Benefit from income taxes |
|
|
(2,124 |
) |
|
|
(3,110 |
) |
|
|
(2,451 |
) |
|
|
(8,310 |
) |
Net loss from consolidated operations |
|
|
(9,090 |
) |
|
|
(11,590 |
) |
|
|
(22,936 |
) |
|
|
(27,439 |
) |
Net loss attributable to noncontrolling interests |
|
|
380 |
|
|
|
361 |
|
|
|
764 |
|
|
|
870 |
|
Net loss attributable to Fulgent |
|
$ |
(8,710 |
) |
|
$ |
(11,229 |
) |
|
$ |
(22,172 |
) |
|
$ |
(26,569 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss attributable to Fulgent: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
$ |
(0.29 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.74 |
) |
|
$ |
(0.90 |
) |
Diluted |
|
$ |
(0.29 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.74 |
) |
|
$ |
(0.90 |
) |
Weighted-average common shares: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
|
30,098 |
|
|
|
29,813 |
|
|
|
29,933 |
|
|
|
29,675 |
|
Diluted |
|
|
30,098 |
|
|
|
29,813 |
|
|
|
29,933 |
|
|
|
29,675 |
|
|
|
|
|
|
|
|
|
|
||||||||
(1) Equity-based compensation expense was allocated as follows: |
|
|
|
|
|
|
|
|
||||||||
Cost of revenue |
|
$ |
1,999 |
|
|
$ |
2,359 |
|
|
$ |
4,008 |
|
|
$ |
4,753 |
|
Research and development |
|
|
4,136 |
|
|
|
3,670 |
|
|
|
7,980 |
|
|
|
7,118 |
|
Selling and marketing |
|
|
1,002 |
|
|
|
1,094 |
|
|
|
2,052 |
|
|
|
2,455 |
|
General and administrative |
|
|
4,498 |
|
|
|
3,200 |
|
|
|
9,113 |
|
|
|
6,262 |
|
Total equity-based compensation expense |
|
$ |
11,635 |
|
|
$ |
10,323 |
|
|
$ |
23,153 |
|
|
$ |
20,588 |
|
FULGENT GENETICS, INC. |
||||||||||||||||
Non-GAAP Income (Loss) Reconciliation |
||||||||||||||||
Three and Six Months Ended June 30, 2024 and 2023 |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net loss attributable to Fulgent |
|
$ |
(8,710 |
) |
|
$ |
(11,229 |
) |
|
$ |
(22,172 |
) |
|
$ |
(26,569 |
) |
Amortization of intangible assets |
|
|
1,990 |
|
|
|
1,962 |
|
|
|
3,980 |
|
|
|
3,930 |
|
Equity-based compensation expense |
|
|
11,635 |
|
|
|
10,323 |
|
|
|
23,153 |
|
|
|
20,588 |
|
Non-GAAP tax effect (1) |
|
|
(224 |
) |
|
|
(3,440 |
) |
|
|
(539 |
) |
|
|
(6,865 |
) |
Non-GAAP income (loss) attributable to Fulgent |
|
$ |
4,691 |
|
|
$ |
(2,384 |
) |
|
$ |
4,422 |
|
|
$ |
(8,916 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per common share attributable to Fulgent: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
$ |
(0.29 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.74 |
) |
|
$ |
(0.90 |
) |
Diluted |
|
$ |
(0.29 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.74 |
) |
|
$ |
(0.90 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Non-GAAP income (loss) per common share attributable to Fulgent: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
$ |
0.16 |
|
|
$ |
(0.08 |
) |
|
$ |
0.15 |
|
|
$ |
(0.30 |
) |
Diluted |
|
$ |
0.15 |
|
|
$ |
(0.08 |
) |
|
$ |
0.15 |
|
|
$ |
(0.30 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
|
30,098 |
|
|
|
29,813 |
|
|
|
29,933 |
|
|
|
29,675 |
|
Diluted |
|
|
30,371 |
|
|
|
29,813 |
|
|
|
30,271 |
|
|
|
29,675 |
|
(1) Tax rates as follows: |
||||||||||||||||
During the three and six months ended June 30, 2024, the Company calculated an income tax provision on a non-GAAP basis. For the three and six months ended June 30, 2023, the Company calculated the non-GAAP tax effect by applying the statutory corporate tax rate on the amortization of intangible assets and equity-based compensation expenses for a tax rate of |
FULGENT GENETICS, INC. |
||||||||||||||||
Non-GAAP Adjusted EBITDA Reconciliation |
||||||||||||||||
Three and Six Months Ended June 30, 2024 and 2023 |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net loss attributable to Fulgent |
|
$ |
(8,710 |
) |
|
$ |
(11,229 |
) |
|
$ |
(22,172 |
) |
|
$ |
(26,569 |
) |
Interest income, net |
|
|
(7,681 |
) |
|
|
(5,003 |
) |
|
|
(15,315 |
) |
|
|
(8,775 |
) |
Benefit from income taxes |
|
|
(2,124 |
) |
|
|
(3,110 |
) |
|
|
(2,451 |
) |
|
|
(8,310 |
) |
Equity-based compensation expense |
|
|
11,635 |
|
|
|
10,323 |
|
|
|
23,153 |
|
|
|
20,588 |
|
Depreciation and amortization |
|
|
6,153 |
|
|
|
6,312 |
|
|
|
12,816 |
|
|
|
13,191 |
|
Adjusted EBITDA |
|
$ |
(727 |
) |
|
$ |
(2,707 |
) |
|
$ |
(3,969 |
) |
|
$ |
(9,875 |
) |
FULGENT GENETICS, INC. |
|
|
|
|
|
|
|
|
||||||||
Non-GAAP Operating Margin |
|
|
|
|
|
|
|
|
||||||||
Three and Six Months Ended June 30, 2024 and 2023 |
|
|
|
|
|
|||||||||||
(in thousands) |
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Revenue |
|
$ |
71,028 |
|
|
$ |
67,853 |
|
|
$ |
135,513 |
|
|
$ |
134,021 |
|
Cost of revenue |
|
|
44,537 |
|
|
|
47,281 |
|
|
|
86,918 |
|
|
|
94,638 |
|
Gross profit |
|
|
26,491 |
|
|
|
20,572 |
|
|
|
48,595 |
|
|
|
39,383 |
|
Gross margin |
|
|
37.3 |
% |
|
|
30.3 |
% |
|
|
35.9 |
% |
|
|
29.4 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Equity-based compensation included in cost of revenue |
|
|
1,999 |
|
|
|
2,359 |
|
|
|
4,008 |
|
|
|
4,753 |
|
Non-GAAP gross profit |
|
|
28,490 |
|
|
|
22,931 |
|
|
|
52,603 |
|
|
|
44,136 |
|
Non-GAAP gross margin |
|
|
40.1 |
% |
|
|
33.8 |
% |
|
|
38.8 |
% |
|
|
32.9 |
% |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses |
|
|
45,397 |
|
|
|
40,370 |
|
|
|
89,299 |
|
|
|
84,005 |
|
Equity-based compensation included in operating expenses |
|
|
9,636 |
|
|
|
7,964 |
|
|
|
19,145 |
|
|
|
15,835 |
|
Amortization of intangible assets |
|
|
1,990 |
|
|
|
1,962 |
|
|
|
3,980 |
|
|
|
3,930 |
|
Non-GAAP operating expenses |
|
|
33,771 |
|
|
|
30,444 |
|
|
|
66,174 |
|
|
|
64,240 |
|
Non-GAAP operating loss |
|
$ |
(5,281 |
) |
|
$ |
(7,513 |
) |
|
$ |
(13,571 |
) |
|
$ |
(20,104 |
) |
Non-GAAP operating margin |
|
|
-7.4 |
% |
|
|
-11.1 |
% |
|
|
-10.0 |
% |
|
|
-15.0 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801327697/en/
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
FAQ
What was Fulgent's total revenue for Q2 2024?
How much did Fulgent's Core Revenue grow year-over-year in Q2 2024?
What is Fulgent's Full Year 2024 Core Revenue Guidance?
What was Fulgent's cash position as of June 30, 2024?